[
    [
        {
            "time": "",
            "original_text": "凯莱英：公司及下属子公司获得政府补助共计约7883万元",
            "features": {
                "keywords": [
                    "凯莱英",
                    "政府补助",
                    "专项补助资金"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英：公司及下属子公司获得政府补助共计约7883万元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)：子公司近日收到专项补助资金784万元",
            "features": {
                "keywords": [
                    "凯莱英",
                    "专项补助资金",
                    "子公司"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：子公司近日收到专项补助资金784万元",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)子公司获专项补助资金784万元",
            "features": {
                "keywords": [
                    "凯莱英",
                    "专项补助资金",
                    "子公司"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)子公司获专项补助资金784万元",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业点评报告：新冠治疗药物机会再梳理：默沙东口服新冠药三期数据积极 年内供应1000万剂",
            "features": {
                "keywords": [
                    "医药生物",
                    "新冠治疗药物",
                    "默沙东",
                    "口服新冠药",
                    "三期数据积极"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业点评报告：新冠治疗药物机会再梳理：默沙东口服新冠药三期数据积极 年内供应1000万剂",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]